List of Excipients in Branded Drug PINDOLOL

« Back to Dashboard

Generic Drugs Containing PINDOLOL

Company	Ingredient	NDC	Excipient
Mylan Pharmaceuticals Inc	pindolol	0378-0052	CELLULOSE, MICROCRYSTALLINE
Mylan Pharmaceuticals Inc	pindolol	0378-0052	CROSCARMELLOSE SODIUM
Mylan Pharmaceuticals Inc	pindolol	0378-0052	MAGNESIUM STEARATE
Mylan Pharmaceuticals Inc	pindolol	0378-0052	SILICON DIOXIDE
Mylan Pharmaceuticals Inc	pindolol	0378-0052	SODIUM LAURYL SULFATE

What are the Most Frequently-Used Excipients in PINDOLOL?

# Of NDCs	Excipient
3	ANHYDROUS LACTOSE
16	CELLULOSE, MICROCRYSTALLINE
8	CROSCARMELLOSE SODIUM
3	CROSPOVIDONE
4	LACTOSE MONOHYDRATE

Pindolol Excipient Strategy and Commercial Opportunities

Last updated: August 9, 2026

Pindolol is an off-patent, immediate-release beta-adrenergic blocker with limited differentiation in conventional tablets. The strongest commercial opportunities are not basic generic replication. They are low-cost, globally scalable formulations that improve swallowability, dose flexibility, supply resilience, or adherence while avoiding unnecessary clinical and regulatory complexity.

Pindolol’s low-dose presentation, alkaline ionization profile, established oral use, and generic status support several formulation paths:

• Immediate-release tablets with improved mechanical performance and low manufacturing cost
• Scored or multiparticulate dosage forms for dose titration
• Orally disintegrating tablets for patients with swallowing difficulty
• Pediatric or geriatric liquid formulations
• Modified-release systems for adherence, although clinical and regulatory returns are less certain
• Coated tablets and packaging systems that address moisture, light, and stability risks

No meaningful U.S. composition-of-matter exclusivity remains for pindolol. Commercial value will depend on cost, geographic access, formulation quality, supply reliability, and channel execution rather than patent barriers.

What is the current FDA and Orange Book status of pindolol?

Pindolol is an established small-molecule prescription beta blocker marketed historically in the United States under the brand name Visken and through generic products. The FDA-approved product is an oral tablet indicated for hypertension, either alone or with other antihypertensive agents [1].

Attribute	Pindolol status
Active ingredient	Pindolol
Drug class	Nonselective beta-adrenergic blocker with intrinsic sympathomimetic activity
Historic brand	Visken
Dosage form	Immediate-release oral tablet
Historic strengths	5 mg, 10 mg, 15 mg, and 20 mg
U.S. regulatory pathway	ANDA generic pathway for eligible products
Biologic status	Not applicable
U.S. patent position	Legacy product and formulation rights are expired or commercially immaterial
Orange Book relevance	Primarily relevant to any currently listed reference or generic products, not to active brand exclusivity
Regulatory exclusivity	No current practical new-drug exclusivity expected for conventional pindolol tablets

The FDA’s Orange Book identifies approved drug products and relevant patent or exclusivity information. For an off-patent small molecule such as pindolol, the key regulatory issue is normally ANDA approval and therapeutic equivalence rather than patent-protected market access [2].

Pindolol does not create a biosimilar opportunity. Biosimilar pathways apply to biological products, while pindolol is a chemically synthesized small molecule. A follow-on product would generally proceed as a generic or, for a materially different dosage form, under an applicable 505(b)(2) strategy.

When does pindolol lose exclusivity?

Pindolol lost practical market exclusivity decades ago. Its historic product approvals predate the modern commercial patent environment for many branded cardiovascular medicines, and conventional tablet products are now exposed to generic competition.

Patent and exclusivity profile

Protection category	Commercial assessment
Composition-of-matter patent	Expired
Original product patent	Expired or no longer commercially relevant
Conventional tablet formulation patents	No meaningful active barrier identified for standard products
Method-of-use patents	No known active U.S. barrier affecting routine hypertension use
Regulatory exclusivity	Expired
Paragraph IV exposure	Low strategic relevance because the core product is already generic
Formulation-specific patents	Potentially available for a new delivery system, but must claim a genuine technical feature
Manufacturing patents	Possible for process improvements, but likely narrow and difficult to enforce

A new excipient system could support a patent only if it produces a non-obvious technical result. A patent directed merely to replacing one common filler with another would face significant validity risk. Stronger claim targets include:

• A defined dissolution profile across pH conditions
• Improved stability under accelerated humidity
• A controlled-release matrix with reproducible pharmacokinetics
• A pediatric liquid with preserved potency over a defined in-use period
• A taste-masking system that maintains rapid release
• A specific multiparticulate architecture
• A manufacturing process that reduces impurity formation or content-uniformity failures

What excipients are suitable for immediate-release pindolol tablets?

A conventional immediate-release pindolol tablet should prioritize dose uniformity, rapid dissolution, low friability, and low manufacturing cost. The excipient platform can remain simple.

Core excipient functions

Function	Candidate excipients	Commercial rationale
Diluent	Lactose monohydrate, microcrystalline cellulose, mannitol, dibasic calcium phosphate	Controls tablet weight and compression behavior
Binder	Povidone, pregelatinized starch, hydroxypropyl cellulose	Improves granule strength and tablet integrity
Disintegrant	Crospovidone, croscarmellose sodium, sodium starch glycolate	Supports rapid tablet breakup
Glidant	Colloidal silicon dioxide	Improves powder flow
Lubricant	Magnesium stearate, sodium stearyl fumarate	Reduces sticking and ejection force
Film former	Hypromellose, polyvinyl alcohol	Improves swallowability and handling
Opacifier or colorant	Titanium dioxide where permitted, iron oxides, approved pigments	Supports product identification
Sweetener	Sucralose, saccharin sodium, aspartame where appropriate	Useful for orally disintegrating or chewable products

The best first-generation platform is likely a direct-compression blend using microcrystalline cellulose, a superdisintegrant, colloidal silicon dioxide, and magnesium stearate. Lactose-based wet granulation may be appropriate where the active ingredient has poor flow or where a manufacturer already operates lactose-compatible equipment.

Pindolol is administered at relatively low strengths. Low-dose products create a higher risk of content-uniformity failure because the active ingredient represents a small fraction of total tablet mass. Granulation or ordered mixing may be preferable to simple blending when the active has poor flow, electrostatic behavior, or segregation risk.

Lactose versus microcrystalline cellulose

Lactose can support low-cost, high-throughput tablets and is consistent with historical product architectures. It may be less attractive where the target market has strong lactose-free positioning or where moisture sensitivity and Maillard-type compatibility concerns arise with an amine-containing drug.

Microcrystalline cellulose provides good compactability and can support direct compression. It may produce tablets with acceptable hardness at lower lubricant levels, but excessive use can slow disintegration or create a bulky tablet.

A dual-diluent system can balance these properties. A practical development screen would compare:

1. Lactose plus crospovidone
2. Microcrystalline cellulose plus croscarmellose sodium
3. Mannitol plus crospovidone for orally disintegrating products
4. Dibasic calcium phosphate for high-density, low-volume tablets

How does pindolol’s chemistry affect excipient selection?

Pindolol is a basic, ionizable compound with an indole-containing structure and a secondary alcohol-containing side chain. Its aqueous behavior is pH-dependent. That affects dissolution testing, liquid formulation design, taste, and compatibility assessment.

pH and ionization

Pindolol’s basic character can support improved apparent solubility in acidic media. A formulation that raises microenvironmental pH may reduce ionization and slow dissolution. This makes alkaline excipients, carbonate systems, and strongly basic buffering agents potential risks unless justified by stability or processing data.

The formulation should screen:

• Microenvironmental pH after tablet disintegration
• Dissolution in acidic and near-neutral media
• Compatibility with alkaline fillers and buffers
• Sorption to polymeric excipients
• Photostability and oxidative degradation
• Stability in aqueous vehicles

A rapid-release tablet should avoid unnecessary hydrophobic excipient loading. High levels of magnesium stearate, hydrophobic coatings, or water-insoluble binders can delay wetting and dissolution.

Compatibility priorities

Compatibility screening should include differential scanning calorimetry, infrared spectroscopy, chromatographic impurity profiling, and accelerated stability. The highest-value screens involve:

• Lactose and other reducing sugars
• Alkaline minerals
• Peroxides in polymeric excipients
• Residual moisture
• Trace metals
• Oxidizing packaging environments

Excipient suppliers should be qualified for peroxide content, particle-size consistency, microbiological quality, and regional compendial compliance. These controls are more commercially relevant than an elaborate excipient patent strategy for a standard tablet.

What formulations are protected or commercially attractive for pindolol?

The most attractive formulation opportunities are dosage forms where the excipient system solves a visible patient or manufacturing problem.

Orally disintegrating tablets

An orally disintegrating tablet could target older patients, patients with dysphagia, and hypertension patients taking multiple medicines. Mannitol, crospovidone, low-substitution hydroxypropyl cellulose, and a taste-masking coating are likely candidates.

The main development risks are bitterness, fragile tablets, moisture uptake, and dose uniformity. Pindolol’s low dose supports a small tablet, but the drug’s taste profile may require polymeric coating, ion-exchange resin complexation, or a multiparticulate taste-masking approach.

A commercially useful ODT should demonstrate:

• Disintegration within the applicable regulatory limit
• Low friability
• Adequate hardness for blister or bottle packaging
• Acceptable mouthfeel
• Rapid drug release after disintegration
• Stability under high humidity

The opportunity is stronger in markets with large geriatric populations or where pharmacies dispense multiple cardiovascular medicines. The product is unlikely to support a premium comparable to modern branded hypertension therapies.

Pediatric or geriatric oral solution

A liquid formulation could address dose titration and swallowing limitations. Potential vehicles include purified water, glycerol, sorbitol solution, polyethylene glycol, and suitable suspending or buffering systems.

The principal risks are chemical stability, microbial control, preservative compatibility, and taste. Because pindolol is a low-dose active, a concentrated solution could reduce administration volume. A suspension may provide a wider formulation window if solubility or stability in solution is inadequate.

Commercially, a ready-to-use liquid has a clearer niche than a generic tablet but also carries higher manufacturing and packaging costs. Unit-dose cups, oral syringes, and child-resistant packaging can create additional differentiation.

Modified-release tablets

A once-daily modified-release product could improve adherence, but the commercial case is weaker than for immediate-release formulations. Pindolol’s historic dosing and established low-cost generic competition would make a premium extended-release product difficult to position without clinical evidence of meaningful benefit.

Candidate systems include:

• Hydrophilic hydroxypropyl methylcellulose matrices
• Ethylcellulose-coated pellets
• Multi-unit minitablets
• Osmotic systems
• Ion-exchange resin complexes

A matrix system is the lowest-complexity option. The formulation must control release across the gastrointestinal pH range and avoid dose dumping. Food-effect studies, alcohol-induced release testing, and comparative pharmacokinetic work would increase development cost.

A modified-release product could potentially support a new formulation patent and a 505(b)(2) application if the clinical and pharmacokinetic package justifies it. Patent value would depend on claim breadth and demonstrated differentiation.

How strong is the patent estate for pindolol formulation products?

The patent estate for standard pindolol tablets is weak because the active ingredient and basic oral dosage form are old. A new formulation could still obtain protection, but the claims would need to focus on a specific technical architecture.

Stronger and weaker patent targets

Patent target	Relative strength
Pindolol molecule	None of practical value
Conventional tablet with standard excipients	Weak
Broad use in hypertension	Weak or unavailable
Specific controlled-release profile	Moderate if supported by data
Taste-masked multiparticulates	Moderate
Stable pediatric solution	Moderate if stability is unexpected
Defined impurity-control process	Moderate to strong if technically narrow
Packaging alone	Usually weak unless tied to demonstrated stability
Routine excipient substitution	Weak

Patent drafting should avoid claiming a broad list of ordinary excipients. The more defensible strategy is a narrow combination claim linked to measurable performance, such as dissolution, stability, impurity suppression, or pharmacokinetics.

Freedom-to-operate analysis should cover active formulation patents in the United States, European Union, India, China, Brazil, and other target markets. Even where U.S. patent barriers are absent, local process, packaging, or combination-product rights may affect launch timing.

What generic entry risks exist for pindolol?

Generic entry risk is already high for standard tablets. A new entrant would face price competition, limited prescriber switching, and potentially low pharmacy reimbursement.

Standard-tablet risk profile

Risk	Impact
Multiple generic suppliers	High
Wholesale price erosion	High
Reference-product substitution	High
Active patent blocking	Low
FDA approval complexity	Low to moderate
Supply-chain interruption	Moderate
Product discontinuation risk	Moderate
Premium pricing potential	Low

The strongest generic opportunity is a reliable low-cost product in an under-supplied strength or geography. The 15 mg strength may offer more differentiation than the widely used 5 mg, 10 mg, and 20 mg presentations, depending on current market availability and purchasing demand.

The main launch risks are not patent litigation. They are manufacturing economics, minimum order quantities, raw-material sourcing, FDA inspection readiness, and whether the product can secure a sustainable wholesaler or government-tender position.

What patent litigation and Paragraph IV issues affect pindolol?

No major current U.S. patent litigation or Paragraph IV campaign is associated with conventional pindolol tablets in the established market. Paragraph IV challenges are generally relevant when an ANDA applicant certifies that a listed patent is invalid, unenforceable, or will not be infringed. For a legacy off-patent product without commercially relevant listed patents, that mechanism has little strategic importance [2,3].

A future formulation applicant could create new patent exposure if it obtains Orange Book-listable patents covering an approved method of use or drug product. That would change the risk profile for later applicants, but it would not restore exclusivity to conventional pindolol tablets.

Settlement agreements are not a central commercial factor in the current pindolol market. Any later dispute would more likely concern a formulation-specific patent, trademark, manufacturing process, or regulatory exclusivity claim than the active ingredient itself.

How does pindolol compare with competing beta blockers?

Pindolol competes against inexpensive and widely recognized beta blockers, including propranolol, metoprolol, atenolol, bisoprolol, and carvedilol. Its intrinsic sympathomimetic activity provides pharmacologic differentiation, but that feature has not produced a durable branded market advantage.

Drug	Formulation competition	Commercial positioning
Pindolol	Generic immediate-release tablets	Niche, low-cost beta blocker
Propranolol	Immediate- and extended-release products, liquids	Broad indications and large generic base
Metoprolol	Immediate- and extended-release products	Strong cardiovascular standard of care
Atenolol	Low-cost tablets	Simple generic hypertension positioning
Bisoprolol	Tablets, strong international use	Cardioselective hypertension and heart-failure positioning
Carvedilol	Immediate- and extended-release products	Heart failure and cardiovascular specialty use

Pindolol’s formulation opportunity is therefore defensive and niche. An ODT, liquid, or carefully designed low-cost tablet may create commercial space, but a conventional tablet will rarely justify substantial development spending unless supported by a supply shortage or an attractive regional tender.

What licensing deals could support a pindolol product?

Licensing is more likely to involve manufacturing and distribution than valuable active-ingredient rights. Potential transaction structures include:

• Contract manufacturing with a regional generic company
• In-licensing of an ODT or liquid technology platform
• Distribution rights for underserved countries
• Supply agreements with hospital or government procurement agencies
• Technology transfer for multiparticulate coating or modified release
• Co-development of pediatric formulations

The most defensible deal structure would link payments to regulatory approval, commercial supply, and minimum purchase volumes. A royalty on a standard tablet would be difficult to justify unless the licensor contributes a protected dosage form, established market access, or a scarce manufacturing capability.

What is the revenue opportunity for pindolol excipient innovation?

Revenue potential is likely modest for standard tablets and higher, but still limited, for differentiated dosage forms.

Product concept	Development cost	Pricing potential	Market attractiveness
Standard immediate-release tablet	Low	Low	Moderate where supply is limited
Scored tablet	Low	Low	Moderate for dose flexibility
ODT	Moderate	Moderate	Selective
Oral solution	Moderate	Moderate	Selective, especially pediatric or geriatric
Extended release	High	Moderate to high	Uncertain
Multiparticulate taste-masked product	Moderate to high	Moderate	Niche
Hospital unit-dose packaging	Low to moderate	Moderate	Regional

Revenue exposure from pindolol is unlikely to resemble that of major branded cardiovascular products. The opportunity is better evaluated as a portfolio extension that uses existing manufacturing assets, regulatory infrastructure, and distribution channels.

Highest-value commercial scenarios

1. A low-cost, supply-secure tablet for a market with limited generic availability
2. A liquid product for pediatric, geriatric, or institutional use
3. An ODT sold through specialty pharmacies and long-term-care channels
4. A regional licensing deal that combines formulation rights with local registration
5. A multi-strength portfolio using a common excipient platform

What manufacturing and IP barriers should developers expect?

Manufacturing barriers are manageable but can determine profitability. Low-dose content uniformity is the central technical issue. Developers should assess:

• Active distribution during blending
• Segregation during hopper discharge
• Blend hold-time effects
• Lubrication sensitivity
• Tablet weight variation
• Dissolution after scale-up
• Coating uniformity for low-strength tablets
• Stability in high-temperature and high-humidity markets

A common formulation platform across 5 mg, 10 mg, 15 mg, and 20 mg strengths can reduce validation and inventory costs. The platform should preserve comparable dissolution and mechanical properties across strengths.

Global excipient selection must account for pharmacopeial status, nitrosamine risk, animal-derived materials, allergen declarations, residual solvents, and local import controls. A formulation that depends on one specialty polymer or a single qualified supplier creates avoidable supply risk.

Key Takeaways

• Pindolol is a mature, off-patent small-molecule beta blocker with no meaningful conventional-tablet exclusivity.
• Immediate-release tablets remain the lowest-risk commercial product but face intense price competition.
• The best excipient strategy emphasizes low-dose content uniformity, rapid dissolution, robust compression, and supply resilience.
• Lactose, microcrystalline cellulose, crospovidone, croscarmellose sodium, povidone, colloidal silicon dioxide, and magnesium stearate are practical starting points.
• ODT and oral-liquid products offer the clearest formulation differentiation.
• Modified release could support new patent claims but carries greater clinical, regulatory, and commercial risk.
• A new formulation patent should claim measurable technical performance rather than routine excipient substitutions.
• Paragraph IV litigation and settlement activity are not central risks for standard pindolol products.
• The most credible commercial strategy is a focused regional or institutional product supported by manufacturing efficiency and reliable supply.

FAQs

Is pindolol still commercially available?

Pindolol availability varies by country, manufacturer, and strength. It has been marketed as Visken and through generic products, but some markets have experienced limited supply or product discontinuations.

Can pindolol be formulated as an orally disintegrating tablet?

Yes. Mannitol, crospovidone, taste-masking polymers, and moisture-protective packaging are plausible components. The principal development challenges are bitterness, friability, humidity stability, and dose uniformity.

Does pindolol have an active composition-of-matter patent?

No practical composition-of-matter exclusivity remains for pindolol. Any current commercial protection would need to arise from a specific formulation, manufacturing process, packaging system, or approved use.

Is a pindolol extended-release product commercially viable?

It is technically feasible but commercially uncertain. The product would require pharmacokinetic differentiation, controlled dissolution across gastrointestinal conditions, and a pricing strategy capable of recovering development costs against inexpensive immediate-release generics.

Which pindolol excipient issue is most important during scale-up?

Low-dose content uniformity is the primary issue. Blend segregation, poor flow, and lubricant overmixing can produce assay variability or delayed dissolution, particularly when the active represents a small percentage of tablet mass.

References

1. U.S. Food and Drug Administration. (n.d.). Pindolol prescribing information. FDA/DailyMed labeling materials.

2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book

3. U.S. Food and Drug Administration. (n.d.). ANDA submissions: Content and format. FDA generic drug guidance and regulatory materials.

4. U.S. Food and Drug Administration. (2013). Waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a biopharmaceutics classification system. Guidance for Industry.

5. United States Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary. USP Convention.

6. World Health Organization. (2023). WHO guideline on stability testing of active pharmaceutical ingredients and finished pharmaceutical products. World Health Organization.